Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID), is a leading life sciences technology company known for its pioneering automation solutions designed to accelerate the manufacturing and safe release of critical healthcare products. The company's flagship product, the Growth Direct™ system, modernizes and automates the otherwise manual microbial quality control (MQC) testing workflows, which are essential in pharmaceutical manufacturing. This revolutionary platform ensures faster detection of microbial contamination, delivering significant economic benefits while enhancing the quality processes of manufacturers.
Headquartered in Lowell, Massachusetts, Rapid Micro Biosystems operates globally with locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands. The company's solutions are pivotal in areas such as biologics, vaccines, cell and gene therapies, and sterile injectables. By automating MQC, the Growth Direct™ system meets current regulatory practices and improves operational efficiency, data integrity, and accuracy.
One of the company's recent milestones includes a collaboration with Samsung Biologics, a top global contract development and manufacturing organization (CDMO), which has adopted the Growth Direct® platform to enhance its microbial quality control processes. This partnership underscores the platform’s capability to handle the scale, data integrity, and speed demanded by modern biomanufacturing.
In 2023, Rapid Micro Biosystems reported a revenue of $22.5 million, reflecting a 31% growth compared to the previous year, and a notable increase in recurring revenue. The company ended the year with approximately $95 million in cash and investments. With a strong financial position and a growth trajectory, the company continues to focus on expanding its product offerings and improving sales and marketing processes.
Rapid Micro Biosystems is also preparing to launch a new Rapid Sterility Application for the Growth Direct® system. This application is a game-changer for sterility testing, reducing time to organism detection to as little as 12 hours and final results within one to three days, a significant improvement over the traditional 14-day incubation period.
Rapid Micro Biosystems (Nasdaq: RPID) is set to release its first quarter 2023 financial results on May 5, 2023, before market opening. The release will be accompanied by a webcast conference call at 8:30 AM EST, which will be accessible for replay for one year. The company specializes in automation solutions that enhance the manufacturing processes for healthcare products, including vaccines and biologics. Their Growth Direct System modernizes microbial quality control testing for pharmaceutical manufacturers, aiming to improve efficiency and compliance. Headquartered in Lowell, Massachusetts, Rapid Micro also has global operations in Europe.
Rapid Micro Biosystems (Nasdaq: RPID) reported fourth quarter 2022 commercial revenue of $4.4 million, down from $5.2 million in Q4 2021. For full year 2022, total revenue was $17.1 million, a decline from $23.2 million in 2021. However, the recurring commercial revenue reached $11.0 million, a significant growth of 40%. The company forecasted 2023 revenue of at least $22.0 million, reflecting an approximate 30% increase. Notably, they maintained $138.4 million in cash with no debt. The net loss for Q4 2022 was $16.4 million, worsening from $14.6 million in Q4 2021.
Rapid Micro Biosystems (Nasdaq: RPID) announced participation in the Cowen 43rd Annual Health Care Conference in Boston on March 8, 2023. The Company's President and CEO Rob Spignesi, along with CFO Sean Wirtjes, will engage in a 30-minute Q&A session starting at 9:10 a.m. Eastern Time. A live webcast will be available on the Company’s investor relations website and can be replayed for 90 days post-event. Rapid Micro Biosystems specializes in automation solutions for healthcare product manufacturing, enhancing microbial quality control with its Growth Direct System. This innovation supports faster results, greater accuracy, and compliance in the production of biologics and vaccines.
Rapid Micro Biosystems (Nasdaq: RPID) will announce its fourth quarter and full year 2022 financial results on March 3, 2023, before market opening. A webcast conference call is scheduled for 8:30 a.m. EST on the same day, with live access via the company's website. The company specializes in automation solutions for the healthcare sector, enhancing the manufacturing and quality control of products such as biologics and vaccines. Their flagship Growth Direct System facilitates faster, more accurate microbial quality control testing, improving operational efficiency and compliance in pharmaceutical manufacturing.
Rapid Micro Biosystems (Nasdaq: RPID) has announced its preliminary unaudited 2022 revenue, expecting total commercial revenue between $17.0 million and $17.2 million. The company finished 2022 with about $140 million in cash, providing operational runway until at least 2026. In Q4 2022, expected revenue is between $4.2 and $4.4 million, with notable placements of two Growth Direct systems and the addition of new global pharma customers. The company will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023.
Rapid Micro Biosystems announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 9:45 AM PT (12:45 PM ET). The company will discuss its innovative automation solutions for healthcare manufacturing. A live webcast will be accessible on the Rapid Micro Biosystems investor relations website and archived for 30 days post-event. Headquartered in Lowell, Massachusetts, the company focuses on modernizing microbial quality control testing in the pharmaceutical industry.
Rapid Micro Biosystems (Nasdaq: RPID) has announced the publication of a case study in the PDA Journal of Pharmaceutical Science and Technology, validating its automated colony counting technology for pharmaceutical microbiology. The research showcases the effectiveness of the Growth Direct system in enhancing quality control with faster results and improved accuracy. Conducted by eight global pharmaceutical firms, the study confirms compliance with regulatory standards. The Growth Direct system is already in routine use for multiple QC tests, supporting safe healthcare product releases.
Rapid Micro Biosystems (Nasdaq: RPID) announced the conclusion of its review of strategic alternatives, revealing that no binding offers were made for acquisition. The Board believes the best path forward is to enhance commercial execution and product development. The company plans to focus on its Growth Direct system, aiming to increase efficiency and customer experience. As of Q3 2022, RPID reported $150.1 million in cash with no debt, providing a cash runway into 2026. The Company continues investing in its solutions to drive growth and shareholder value.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) reported third quarter 2022 commercial revenue of $4.7 million, down from $6.3 million in Q3 2021. However, the company achieved a 34% year-over-year growth in recurring revenue, totaling $2.9 million. The company reaffirmed its full-year revenue guidance of at least $17 million, anticipating the placement of two additional systems in Q4. Despite a net loss of $16.3 million, improved cash reserves of $150.1 million and a comprehensive review of strategic alternatives aim to maximize shareholder value.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) will announce its third quarter 2022 financial results on November 10, 2022, before the market opens. Following the release, management will host a conference call at 8:30 a.m. EST. The company focuses on providing innovative automation solutions for the healthcare industry, including the Growth Direct System that modernizes microbial quality control testing. This advancement enhances efficiency and compliance, crucial for the safe production of healthcare products. For more details, visit the company's website.